Advancing the current state of gene therapies using adeno-associated virus vectors to treat atrial cardiomyopathy
Gene therapies provide an opportunity to treat ACM at the root cause beyond the management of its sequelae. However, solutions aiming to improve vector design, manufacturability and suitability for ACM should be adopted to improve therapeutic efficacy and broaden patient accessibility.
Authors
- Shinya Tsurusaki (ORCID: https://orcid.org/0000-0002-2592-4555)
- Eddy Kizana (ORCID: https://orcid.org/0000-0002-7266-6720)
- Juan Mundisugih (ORCID: https://orcid.org/0000-0003-0720-077X)
- Natsuki Sasaki (ORCID: https://orcid.org/0009-0001-9633-0180)
- Peter Emerson (ORCID: https://orcid.org/0000-0002-8752-0687)
- Ivy K N Chiang
- Ahmad Hammoud
Institutions
- The University of Sydney (AU)
- Westmead Hospital (AU)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1080/17425247.2025.2610390
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00